No Data
No Data
Optimistic Buy Rating on PureTech Health Driven by Promising LYT-100 Developments and Strategic Growth Plans
PureTech Health's Earnings Call: Achievements and Challenges
Express News | PureTech Says It Will Present Results From Phase 2b ELEVATE IPF Trial Of Deupirfenidone (LYT-100) At American Thoracic Society International Conference, Regulatory And Strategic Planning Underway To Advance Deupirfenidone Into Phase 3 Development
PureTech Health Plc (PRTC) Q4 2024 Earnings Call Transcript Summary
20-F: FY2024 Annual Report
6-K: Report of foreign private issuer (related to financial reporting)